Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis?

Liu C, Playford ED, Thompson AJ.

J Neurol. 2003 Oct;250(10):1214-8.

PMID:
14586605
2.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
3.

Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis.

Khan F, Pallant JF, Turner-Stokes L.

Arch Phys Med Rehabil. 2008 Apr;89(4):652-9. doi: 10.1016/j.apmr.2007.09.049.

PMID:
18373995
4.

[Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].

Gaillard N, Fabro-Perray P, Faillie JL, Le Bayon A, Castelnovo G, Dupeyron A, Froger J, Pelissier J, Labauge P.

Rev Neurol (Paris). 2007 Jan;163(1):72-81. French.

PMID:
17304175
5.

[Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

Mesaros S, Stojsavljević N, Dujmović I, Mandić E, Drulović J.

Srp Arh Celok Lek. 2004 Jul-Aug;132(7-8):209-13. Serbian.

6.

Prognostic factors in multiple sclerosis rehabilitation.

Grasso MG, Pace L, Troisi E, Tonini A, Paolucci S.

Eur J Phys Rehabil Med. 2009 Mar;45(1):47-51. Epub 2009 Mar 9.

7.

Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients--a randomised controlled trial.

Patti F, Ciancio MR, Cacopardo M, Reggio E, Fiorilla T, Palermo F, Reggio A, Thompson AJ.

J Neurol. 2003 Jul;250(7):861-6.

PMID:
12883930
8.
10.

The impact of inpatient rehabilitation on progressive multiple sclerosis.

Freeman JA, Langdon DW, Hobart JC, Thompson AJ.

Ann Neurol. 1997 Aug;42(2):236-44.

PMID:
9266735
12.

Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.

Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E.

Acta Neurol Scand. 2002 Mar;105(3):164-8.

PMID:
11886358
13.

The psychometric properties of clinical rating scales used in multiple sclerosis.

Sharrack B, Hughes RA, Soudain S, Dunn G.

Brain. 1999 Jan;122 ( Pt 1):141-59.

PMID:
10050902
14.

Multiple sclerosis: relapses and timing of remissions.

Iuliano G, Napoletano R, Esposito A.

Eur Neurol. 2008;59(1-2):44-8. Epub 2007 Oct 4.

PMID:
17917457
15.

Physical rehabilitation has a positive effect on disability in multiple sclerosis patients.

Solari A, Filippini G, Gasco P, Colla L, Salmaggi A, La Mantia L, Farinotti M, Eoli M, Mendozzi L.

Neurology. 1999 Jan 1;52(1):57-62.

PMID:
9921849
16.

Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.

Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BM.

Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.

PMID:
18184917
17.

Evaluating neurorehabilitation: lessons from routine data collection.

Freeman JA, Hobart JC, Playford ED, Undy B, Thompson AJ.

J Neurol Neurosurg Psychiatry. 2005 May;76(5):723-8.

18.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
19.

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M.

Neurology. 2004 Feb 24;62(4):601-6. Review.

PMID:
14981177
20.

[Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients].

Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Edan G.

Rev Neurol (Paris). 2006 Feb;162(2):185-94. French.

PMID:
16518258

Supplemental Content

Support Center